The CF Foundation expressed support to members of the Wisconsin State Legislature on LRB 1683/1, legislation that would provide a number of measures to protect patients’ access to medication, including requiring insurers to apply third-party assistance to out-of-pocket-maximums and other patient cost-sharing requirements.
Site Search
CF Foundation joins 1,098 organizations strongly urging Congressional leadership to finish the FY24 appropriations process and adopt the bipartisan Senate funding framework as a starting point for final negotiations.
The Cystic Fibrosis Foundation joined the Partnership for Protecting Coverage in providing feedback to the Departments of Treasury, Labor, Health and Human Services, and the Office of Personnel Management on new provisions outlined in the No Surprises Act.
In the statement, the Partnership for Protecting Coverage applauded efforts by the Department of Labor to reverse previous decisions to eliminate or substantially alter standards and regulatory structures of association health plans, including requiring these plans to cover essential health benefits.
In the letter to the Federal Trade Commission, the Cystic Fibrosis Foundation asks the commissioner to take appropriate enforcement action against alternative funding programs, emphasizing the harmful consequences of these programs on people with CF.
The Cystic Fibrosis Foundation joined other patient advocacy organizations in providing comments to Nevada’s Department of Health and Human Services requesting pass-through funds to implement a coverage program that would improve access to affordable coverage in the state.
Ad hoc patient advocacy coalition provided feedback to the U.S. Department of Health and Human Services on North Carolina’s proposal to provide continuous program eligibility for children.
Ad hoc patient advocacy coalition provided feedback to the U.S. Department of Health and Human Services on Maryland’s proposal to make permanent policies that would make the program eligibility review process timelier and more efficient, reducing the administration burden faced by the patient.
In a letter to the Senate Finance Committee, the Cystic Fibrosis Foundation, along with an ad hoc patient coalition, cited support for the provision included in the Modernizing and Ensuring PBM Accountability Act that would prohibit pharmacy benefit managers from being compensated for Medicare Part D covered drugs based on the manufacturer’s lis
In their response to the House Budget Committee’s request, the Partnership for Protecting Coverage outlined three overarching principles to guide health care reform and improve the U.S. health care system.